



Sales of Genetically Manufactured Pharmaceuticals

Share of biopharmaceuticals in the entire German pharmaceutical market (2008)



Sales of biopharmaceuticals in Germany in EUR million (2008)



Sales at manufacturer prices in the pharmacy market

¹ Excl. hematological oncology

² Incl. gastroenterology, dermatology, urology, etc.

Source: vfa member companies, EvaluatePharma, BCG analysis

The share of pharmaceuticals with genetically manufactured substances is constantly increasing: With EUR 4.4 billion in sales in 2008, (at manufacturer prices) it was 16 percent. In 2000, this share was still at 8 percent.

About 40 percent of sales fall into applications of metabolism (especially insulins for treating diabetes) and infections (especially vaccines) and insulins. Additional important applications include interferons used for immune disorders, monoclonal antibodies against cancer and EPO (erythropoietin) against anemia.